The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products

被引:59
作者
Fischer, L.
Hornig, M.
Pergola, C.
Meindl, N.
Franke, L.
Tanrikulu, Y.
Dodt, G.
Schneider, G.
Steinhilber, D.
Werz, O.
机构
[1] Univ Tubingen, Dept Pharmaceut Analyt, Inst Pharm, Tubingen, Germany
[2] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-6000 Frankfurt, Germany
[3] Goethe Univ Frankfurt, Inst Organ Chem, D-6000 Frankfurt, Germany
[4] Univ Tubingen, Interfak Inst Biochem, Tubingen, Germany
关键词
5-lipoxygenase; 5-lipoxygenase-activating protein; leukotriene; inflammation; arachidonic acid; polymorphonuclear leukocytes;
D O I
10.1038/sj.bjp.0707416
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: Licofelone is a dual inhibitor of the cyclooxygenase and 5- lipoxygenase ( 5- LO) pathway, and has been developed for the treatment of inflammatory diseases. Here, we investigated the molecular mechanisms underlying the inhibition by licofelone of the formation of 5- LO products. Experimental approach: The efficacy of licofelone to inhibit the formation of 5- LO products was analysed in human isolated polymorphonuclear leukocytes ( PMNL) or transfected HeLa cells, as well as in cell- free assays using respective cell homogenates or purified recombinant 5- LO. Moreover, the effects of licofelone on the subcellular redistribution of 5- LO were studied. Key results: Licofelone potently blocked synthesis of 5- LO products in Ca2+- ionophore- activated PMNL ( IC50=1.7 mu M) but was a weak inhibitor of 5- LO activity in cell-free assays (IC50>>10 mu M). The structures of licofelone and MK-886, an inhibitor of the 5-LO- activating protein ( FLAP), were superimposable. The potencies of both licofelone and MK- 886 in ionophore- activated PMNL were impaired upon increasing the concentration of arachidonic acid, or under conditions where 5- LO product formation was evoked by genotoxic, oxidative or hyperosmotic stress. Furthermore, licofelone prevented nuclear redistribution of 5- LO in ionophore- activated PMNL, as had been observed for FLAP inhibitors. Finally, licofelone as well as MK- 886 caused only moderate inhibition of the synthesis of 5- LO products in HeLa cells, unless FLAP was co- transfected. Conclusions and implications: Our data suggest that the potent inhibition of the biosynthesis of 5- LO products by licofelone requires an intact cellular environment and appears to be due to interference with FLAP.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 50 条
  • [21] On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo
    Pergola, C.
    Jazzar, B.
    Rossi, A.
    Northoff, H.
    Hamburger, M.
    Sautebin, L.
    Werz, O.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (03) : 765 - 776
  • [22] BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly
    Garscha, Ulrike
    Voelker, Susanna
    Pace, Simona
    Gerstmeier, Jana
    Emini, Besa
    Liening, Stefanie
    Rossi, Antonietta
    Weinigel, Christina
    Rummler, Silke
    Schubert, Ulrich S.
    Scriba, Gerhard K. E.
    Celikoglu, Ersan
    Caliskan, Burcu
    Banoglu, Erden
    Sautebin, Lidia
    Werz, Oliver
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 17 - 26
  • [23] Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor
    Hofmann, B.
    Roedl, C. B.
    Kahnt, A. S.
    Maier, T. J.
    Michel, A. A.
    Hoffmann, M.
    Rau, O.
    Awwad, K.
    Pellowska, M.
    Wurglics, M.
    Wacker, M.
    Zivkovic, A.
    Fleming, I.
    Schubert-Zsilavecz, M.
    Stark, H.
    Schneider, G.
    Steinhilber, D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (07) : 2304 - 2313
  • [24] Phenolic acid phenethylesters and their corresponding ketones: Inhibition of 5-lipoxygenase and stability in human blood and HepaRG cells
    Mbarik, Maroua
    Poirier, Samuel J.
    Doiron, Jeremie
    Selka, Ayyoub
    Barnett, David A.
    Cormier, Marc
    Touaibia, Mohamed
    Surette, Marc E.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (05):
  • [25] Therapeutic options for 5-lipoxygenase inhibitors
    Werz, Oliver
    Steinhilber, Dieter
    PHARMACOLOGY & THERAPEUTICS, 2006, 112 (03) : 701 - 718
  • [26] 5-lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents
    Jampilek, J
    Dolezal, M
    Opletalova, V
    Hartl, J
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (02) : 117 - 129
  • [27] Licofelone, a dual cyclooxygenase/5-lipoxygenase inhibitor, reverses endotoxin-induced impaired atrial chronotropic responsiveness to cholinergic stimulation in rats
    Nikoui, Vahid
    Mehrzadi, Saeed
    Khan, Muhammad Imran
    Aman, Waqar
    Ostadhadi, Sattar
    Dehpour, Ahmad Reza
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 887
  • [28] Biosynthesis of hemiketal eicosanoids by cross-over of the 5-lipoxygenase and cyclooxygenase-2 pathways
    Griesser, Markus
    Suzuki, Takashi
    Tejera, Noemi
    Mont, Stacey
    Boeglin, William E.
    Pozzi, Ambra
    Schneider, Claus
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (17) : 6945 - 6950
  • [29] Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds
    Werz, O
    Steinhilber, D
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (05) : 505 - 519
  • [30] The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages
    Rossi, A.
    Pergola, C.
    Koeberle, A.
    Hoffmann, M.
    Dehm, F.
    Bramanti, P.
    Cuzzocrea, S.
    Werz, O.
    Sautebin, L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (03) : 555 - 570